President, Director & Chief Executive Officer
SemaThera Inc
The startup develops anti-SEMA 3A therapies targeting ocular diseases such as diabetic macular edema and wet age-related macular degeneration. By providing protein inhibitors, the company enables physicians to treat these retinopathies and potentially address related neurodegenerative conditions.
- Biotechnology
Updated 21 months ago
Funding
Raised to date
$3.6MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops anti-SEMA 3A therapies targeting ocular diseases such as diabetic macular edema and wet age-related macular degeneration. By providing protein inhibitors, the company enables physicians to treat these retinopathies and potentially address related neurodegenerative conditions.